Published in Eur Respir J on February 01, 2002
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med (2006) 3.16
Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax (2004) 2.78
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax (2006) 1.76
Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res (2006) 1.69
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med (2010) 1.64
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis (2010) 1.51
Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis (2008) 1.46
Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ (2010) 1.41
A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J (2007) 1.40
Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis (2010) 1.35
Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol (2013) 1.26
Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol (2005) 1.24
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol (2006) 1.17
Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax (2003) 1.16
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res (2010) 1.12
A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis (2007) 1.11
Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res (2007) 1.08
Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol (2011) 1.07
COPD exacerbations . 3: Pathophysiology. Thorax (2006) 1.06
The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol (2008) 1.06
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax (2005) 1.02
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.99
Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.99
Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med (2014) 0.99
Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed (2006) 0.95
Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.95
Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med (2010) 0.95
The Saudi Guidelines for the Diagnosis and Management of COPD. Ann Thorac Med (2014) 0.92
Differential assessment and management of asthma vs chronic obstructive pulmonary disease. Medscape J Med (2009) 0.91
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis (2014) 0.91
Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.91
A bibliometric analysis of the 100 most influential papers on COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.90
Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation. Postgrad Med J (2004) 0.89
Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.89
COPD exacerbations. 4: Prevention. Thorax (2006) 0.88
Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway. Cell Tissue Res (2012) 0.87
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.87
Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis (2015) 0.87
Optimising treatment for COPD--new strategies for combination therapy. Int J Clin Pract (2009) 0.87
Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Proc (Bayl Univ Med Cent) (2004) 0.86
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis (2009) 0.86
Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis (2008) 0.86
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res (2010) 0.84
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist. Core Evid (2010) 0.84
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.83
Management of an acute exacerbation of copd: are we ignoring the evidence? Thorax (2002) 0.83
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Tiotropium bromide: an update. Open Respir Med J (2009) 0.82
The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respir Res (2016) 0.82
The development of anticholinergics in the management of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.81
Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.81
Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.80
Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease. Lung (2006) 0.80
Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chron Obstruct Pulmon Dis (2008) 0.79
The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res (2009) 0.79
Integrating COPD into Patient-Centered Hospital Readmissions Reduction Programs. Chronic Obstr Pulm Dis (2015) 0.79
The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci (2007) 0.79
Small airways ventilation heterogeneity and hyperinflation in COPD: response to tiotropium bromide. Int J Chron Obstruct Pulmon Dis (2007) 0.78
Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis (2010) 0.78
Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis (2007) 0.78
Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.78
Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators. Tanaffos (2012) 0.77
Tiotropium in the management of chronic obstructive pulmonary disease. Eur Respir J (2002) 0.77
Effect of aging on airway remodeling and muscarinic receptors in a murine acute asthma model. Clin Interv Aging (2013) 0.76
Tiotropium bromide. Int J Chron Obstruct Pulmon Dis (2006) 0.76
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res (2016) 0.76
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res (2010) 0.76
Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. PLoS One (2016) 0.75
Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res (2016) 0.75
Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat soft mist inhaler: findings from two dose-ranging studies in healthy men. Int J Chron Obstruct Pulmon Dis (2008) 0.75
Optimizing bronchodilator therapy in emphysema. Proc Am Thorac Soc (2008) 0.75
Predicting chronic obstructive pulmonary disease hospitalizations based on concurrent influenza activity. COPD (2013) 0.75
Arandomized multicenter Phase II study of perioperative tiotropium intervention in gastric cancer patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.75
MODELING CHRONIC DISEASE PATIENT FLOWS DIVERTED FROM EMERGENCY DEPARTMENTS TO PATIENT-CENTERED MEDICAL HOMES. IIE Trans Healthc Syst Eng (2016) 0.75
Efficacy of Tiotropium Bromide and Rehabilitation Treatment on Pulmonary Function of Patients With Sulfur Mustard Lung Injury. Iran Red Crescent Med J (2015) 0.75
Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax (2015) 0.75
Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study. Int J Chron Obstruct Pulmon Dis (2012) 0.75
Palliative care for patients with chronic obstructive pulmonary disease: current perspectives. Indian J Palliat Care (2012) 0.75
"What are my chances of developing COPD if one of my parents has the disease?" A systematic review and meta-analysis of prevalence of co-occurrence of COPD diagnosis in parents and offspring. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair(®) versus HandiHaler(®) in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis (2012) 0.75
[Chronic obstructive lung disease]. Internist (Berl) (2003) 0.75
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53
Regular vs as-needed inhaled salbutamol in asthma control. Lancet (1994) 3.59
Bronchodilator responsiveness in patients with COPD. Eur Respir J (2008) 3.13
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J (2005) 2.60
The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med (2008) 2.21
Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest (1994) 2.15
Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J (2007) 2.03
Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J (2010) 2.01
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax (2003) 1.93
Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med (2001) 1.69
Physiologic and nonphysiologic determinants of aerobic fitness in mild to moderate asthma. Am Rev Respir Dis (1992) 1.66
Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J (2009) 1.52
Bronchiolitis obliterans after lung transplantation: a review. Chest (1998) 1.45
Adverse effects of inhaled corticosteroids. Am J Med (1995) 1.39
24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther (2011) 1.38
A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax (2000) 1.38
Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol (2013) 1.26
Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med (2010) 1.23
Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med (1998) 1.23
Psychological functioning and quality of life in lung transplant candidates and recipients. Chest (2000) 1.20
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19
Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther (2005) 1.19
Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol (1999) 1.18
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther (2004) 1.17
Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med (2003) 1.15
The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant (1997) 1.14
Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol (1995) 1.13
Comparison of hallway and treadmill six-minute walk tests. Am J Respir Crit Care Med (1999) 1.11
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J (2002) 1.09
Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Eur Respir J (1996) 1.08
Aspergillus infection in single and double lung transplant recipients. Transplantation (1996) 1.06
COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med (2010) 1.05
Factors associated with emergency department dependence of patients with asthma. Chest (1997) 1.04
Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation (1997) 1.04
Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med (2001) 1.03
Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med (2007) 1.01
Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). Respir Med (2013) 0.96
Total respiratory resistance and reactance in patients with upper airway obstruction. Chest (1987) 0.95
Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J (2009) 0.94
Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med (2003) 0.93
Variability in performance of timed walk tests in pulmonary rehabilitation programs. Chest (2000) 0.93
Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg (1995) 0.90
Primary extranodal non-Hodgkin's lymphoma of the lung presenting with bilateral, patchy infiltrates dramatically improving after corticosteroid therapy. Chest (1993) 0.90
Exhaled nitric oxide in human lung transplantation. A noninvasive marker of acute rejection. Am J Respir Crit Care Med (1998) 0.88
Prior diagnosis and treatment of patients with normal results of methacholine challenge and unexplained respiratory symptoms. Chest (1996) 0.88
Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest (1996) 0.88
The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma (2000) 0.87
Causes of death in lung transplant recipients. J Heart Lung Transplant (1995) 0.87
Return to work after lung transplantation. J Heart Lung Transplant (1998) 0.86
Pulmonary sarcoid-like granulomata in a patient treated for extrapulmonary Hodgkin's disease. Respiration (1997) 0.86
Hepatitis C virus infection and lung transplantation: a survey of practices. J Heart Lung Transplant (1999) 0.86
Quality of life in female lung transplant candidates and recipients. Chest (1997) 0.85
Assessment of an ambulatory care asthma program. J Asthma (1994) 0.85
Status of lung transplant recipients surviving beyond five years. J Heart Lung Transplant (1997) 0.84
Small cell lung cancer with paraneoplastic nephrotic syndrome. Eur Respir J (1994) 0.83
Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother (1984) 0.83
Miliary pulmonary cryptococcosis in a patient with the acquired immunodeficiency syndrome. Thorax (1993) 0.83
Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2006) 0.82
Severe pulmonary hypertension associated with COPD. Ann Transplant (2000) 0.82
Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med (2007) 0.82
Prospective assessment of a standardized pathologic grading system for acute rejection in lung transplantation. Chest (1993) 0.81
Asthma and allergy avoidance knowledge and behavior in postpartum women. Ann Allergy Asthma Immunol (1997) 0.81
Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant (1996) 0.81
Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. Pulm Pharmacol Ther (2004) 0.81
Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Chest (1997) 0.81
The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest (1998) 0.80
Effects of high-dose inhaled fluticasone propionate via spacer on cell-mediated immunity in healthy volunteers. Chest (2000) 0.80
Lung volume reduction surgery: an analysis of hospital costs. Chest (1998) 0.80
Analysis of the T cell receptor Vgamma region gene repertoire in bronchoalveolar lavage (BAL) and peripheral blood of atopic asthmatics and healthy subjects. Clin Exp Immunol (1996) 0.80
Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime. J Antimicrob Chemother (1983) 0.79
A retrospective comparative study of in-hospital management of acute severe asthma: 1984 vs 1989. Chest (1993) 0.79
Canada's First National Conference on Asthma and Education. Consideration of public programs and techniques for public/community health education. Chest (1994) 0.78
Doxycycline in respiratory infections: a re-assessment after 17 years. J Antimicrob Chemother (1986) 0.78
Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans. Am J Respir Crit Care Med (1999) 0.78
Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest (1998) 0.78
Diaphragmatic paralysis: a complication of lung transplantation. Ann Thorac Surg (1996) 0.77
Skeletal muscle dysfunction in lung transplantation. J Heart Lung Transplant (2000) 0.77
A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group. J Allergy Clin Immunol (1990) 0.77
Effect of rib cage and abdominal restriction on total respiratory resistance and reactance. J Appl Physiol (1985) (1986) 0.77
Acute lung injury in lung allografts. J Heart Lung Transplant (1995) 0.77
Effect of zatebradine, a novel 'sinus node inhibitor', on pulmonary function compared to placebo. Pulm Pharmacol (1994) 0.76
Comorbidities in end-stage lung disease. J Heart Lung Transplant (1999) 0.76
A large air-filled cyst in a patient with migratory infiltrates. Chest (1994) 0.76
Brodimoprim in acute exacerbations of chronic bronchitis: a clinical and bacteriological pilot study. J Antimicrob Chemother (1984) 0.75
Pulmonary sequestration with congenital broncho-oesophageal fistula. Eur Respir J (1990) 0.75
Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant (1996) 0.75
Gas trapping as a predictor of positive methacholine challenge in patients with normal spirometry results. Chest (1995) 0.75
Infections in lung transplant recipients. Clin Chest Med (1997) 0.75
Is survival that important? J Heart Lung Transplant (1998) 0.75
Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc (1993) 0.75
[Opportunistic lung infections in patients with chronic obstructive pulmonary disease; a side effect of inhalation corticosteroids?]. Ned Tijdschr Geneeskd (1996) 0.75
Bronchodilator responsiveness in patients with COPD (data from the UPLIFT trial). Rev Port Pneumol (2015) 0.75
Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg (1994) 0.75
Cavitary aspergillosis as a complication of AIDS. Can Assoc Radiol J (1993) 0.75
Multi-organ donor transmission of hepatitis C virus to five solid organ transplant recipients and lack of transmission to corneal transplant recipients. Clin Diagn Virol (1995) 0.75